Gelonghui, January 29丨Meibang Co., Ltd. (605033.SH) announced the pre-reduction announcement for the 2023 annual results. According to preliminary estimates by the financial department, the company expects to achieve net profit attributable to shareholders of listed companies in 2023 of about 52-65 million yuan. Compared with the same period last year (statutory disclosure data), it will decrease by 80,000-93.09 million yuan, a year-on-year decrease of 55%-64%. Net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses in 2023 is expected to be approximately RMB 36.04-49.04 million. Compared with the same period of the previous year (statutory disclosure data), it will decrease by RMB 8244-95.44 million, a year-on-year decrease of 63%-73%.
The main reason for the decline in the company's net profit attributable to shareholders of listed companies in 2023 is that the price of original drugs has continued to decline since the second half of 2022, and the price of raw materials purchased by the company in the early stages is high, resulting in a relatively high unit cost of biocides and pesticides sold by the company in 2023. Furthermore, due to various factors such as domestic policy, economy, and climate, market competition intensified. In 2023, the company adopted a sales strategy that mainly digests inventory. The company's product sales volume, production, and sales prices all declined year on year, causing the company's overall performance to decline.